2-(3,4-dimethoxyphenyl)-1-(2-phenylethyl)-1H-benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(3,4-dimethoxyphenyl)-1-(2-phenylethyl)-1H-benzimidazole
• 英文别名: 2-(3,4-dimethoxyphenyl)-1-(2-phenylethyl)benzimidazole
• 化学式: C₂₃H₂₂N₂O₂
• mdl: MFCD02630700
• 分子量: 358.4
• InChiKey: GVYWMYSDOWADQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Compounds that enhance Atoh-1 expression
  申请人：MASSACHUSETTS EYE & EAR INFIRMARY

  公开号：EP2732819A2

  公开（公告）日：2014-05-21

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g. a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中 Atoh1 基因（如 Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：EP2254572B1

  公开（公告）日：2013-10-16
• Compounds that Enhance Atoh1 Expression
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：US20150157607A1

  公开（公告）日：2015-06-11

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
• Compounds That Enhance ATOH1 Expression
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：US20170095481A1

  公开（公告）日：2017-04-06

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
• US8859597B2
  申请人：——

  公开号：US8859597B2

  公开（公告）日：2014-10-14